Compare 14 GxP compliance services partners delivering computerised system validation, data-integrity assurance, and regulatory-readiness programmes for life-sciences organisations subject to FDA 21 CFR Part 11, EU GMP Annex 11, ICH Q9 quality risk management, GAMP 5 second-edition guidance, and the data-integrity principles spelled out by MHRA, EMA, FDA, and PIC/S. Engagements cover the validation lifecycle for laboratory information management systems, manufacturing execution systems, electronic batch records, clinical trial management, pharmacovigilance, regulatory information management, and ERP estates, the periodic-review cadence, audit-trail design, electronic-signature and ALCOA-plus controls, supplier-assessment and Annex 11 supplier-management, and the inspection-readiness pack for FDA, EMA, and PMDA audits. Listings cover Big Four life-sciences advisories, validation specialists, India-heritage SI pharma practices, and the GxP boutique consultancies. No partner pays for placement on this directory.
GxP engagements break into four typical workstreams. Validation lifecycle, where the partner authors the validation plan, user-requirement and functional-specification documents, the risk assessment under ICH Q9 and GAMP 5 categorisation, the test scripts for installation, operational and performance qualification, the traceability matrix, and the validation summary report for each computerised system. Data integrity and ALCOA-plus, where the partner reviews audit-trail design, electronic-signature controls, access management, time-stamp accuracy, change-control linkage, and the data-flow analysis from instrument through laboratory and quality-management systems. Supplier and Annex 11 management, where the partner runs supplier assessments, sets quality-agreement templates, evaluates SaaS and cloud-deployed regulated systems against the supplier-responsibility split, and builds the periodic-review programme. Inspection readiness and remediation, where the partner builds the FDA Form 483 and EMA inspection-response runbook, runs mock-inspection exercises, prepares the inspection-ready evidence binders, and remediates findings against CAPA timelines.
Three procurement archetypes recur. Big Four life-sciences practices (Deloitte, PwC, KPMG, EY, plus Accenture Life Sciences) lead where GxP sits inside a multi-year quality-transformation programme spanning multiple sites and modalities, the buying centre is the global quality head, and the engagement bundles regulatory strategy with system delivery. Life-sciences specialists and India-heritage SIs (IQVIA, ProPharma, NNIT, TCS, Infosys, Wipro) lead on factory-scale validation, multi-site rollouts, and sustained periodic-review operations at predictable cost. Validation boutiques (Azzur, CSols, ValGenesis services) lead on the deepest technical work, including complex LIMS validation, MES re-validation, and post-Annex-11 remediation. Friction point: cloud and SaaS adoption is reshaping validation effort but the regulatory expectation has not relaxed in step, and many programmes underestimate the supplier-assessment workload for multi-tenant SaaS where the sponsor cannot rely on shared validation evidence; the gap is typically 30-50% additional effort across the first year.
For complementary research see LIMS platforms, MES platforms, quality management, regulatory information management, and clinical trial management. For adjacent services see pharma and life sciences IT consulting, Veeva implementation, SAP implementation, ISO 27001 implementation, data privacy and GDPR, and quality assurance and testing.
Tell us what you're evaluating and we'll send a tailored shortlist of vendors that actually fit — no vendor funding, no pay-to-play.
6,000+ vendors · 893 comparisons · 48 country guides · Independent & vendor-neutral